Sorafenib in Liver, Kidney and Thyroid Cancer: — Three Different Uses

No. Sorafenib is a targeted therapy, not chemotherapy. Chemotherapy works by attacking all rapidly dividing cells throughout the body. Sorafenib works differently — it blocks specific proteins that cancer cells rely on to grow and build blood vessels. The side effects are also different. Where chemotherapy commonly causes hair loss and nausea, sorafenib is more associated with a skin reaction on the palms and soles, fatigue, diarrhoea and raised blood pressure. Your oncology nurse will go through what to expect before you start.

No. In early-stage liver cancer where surgery, liver transplant or ablation is still possible, sorafenib is not part of the treatment plan. Those approaches are more effective when the disease is localised. NCCN and ESMO guidance positions sorafenib for advanced liver cancer — meaning disease that has spread or grown in a way that makes local treatment no longer the right option. If you have been offered sorafenib, your oncologist has assessed that the disease is at that stage. It is entirely reasonable to ask them to explain exactly why local treatment is no longer being recommended.

Radioactive iodine works well for differentiated thyroid cancer while the cells still absorb it, and it reaches the tumour precisely with a different side effect profile. Once a thyroid cancer stops absorbing iodine — confirmed through scans — that treatment can no longer reach the tumour effectively. At that point, NCCN and ESMO guidance supports targeted therapies such as sorafenib for disease that is growing or has spread. Using sorafenib when radioactive iodine still works would expose you to its side effects without adding benefit.

Sorafenib is taken as oral tablets at home on a schedule your oncologist will set — it is not given by infusion in hospital. There are specific instructions about food that your pharmacist or oncology nurse will explain, because what you eat around the time you take it can affect how the drug is absorbed. Taking it consistently at the same time each day matters. If you miss a dose, or a side effect makes it difficult to take, call your team before changing anything. Dose adjustments are sometimes needed and should always be made by your oncologist, not independently.

They work in entirely different ways. Sorafenib is a targeted therapy that blocks proteins tumour cells and their blood vessels depend on. Immunotherapy removes the brakes on your own immune system so it can recognise and attack cancer cells. Both are used in kidney cancer, for example, but for different patients and sometimes in different sequences. Whether you receive one, the other, or both in combination depends on your cancer subtype, your test results, your fitness and what treatment you have already had. Your oncologist will explain the reasoning behind what has been chosen for you.

If your cancer grows on sorafenib, your oncologist will reassess what to do next. The options depend on which cancer you have, how much the disease has progressed, your general fitness and what you have already received. For kidney cancer, other systemic options are available. For liver cancer, other drugs are used in later lines. For thyroid cancer, other targeted drugs are approved for radioactive iodine-refractory disease. One targeted drug stopping working does not mean all options are gone. Ask your oncologist specifically what the plan would be if sorafenib stops controlling the disease — having that conversation early is useful.